Total Funding
23
46
Total FundingSeries A raised
Growth Score 23 in past quarter
0 pts
Heat Score 46 in past quarter
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
74630
Biosceptre has identified a cancer target, nf-P2X7, present in many cancer types, and importantly not found in healthy tissue.
- Gavin Currie: Chief Executive Officer
- Braden Roberts: Chief Business Officer
About the Company
Biosceptre is driving innovation to bring new and progressive therapies to a wide range of cancer patients. Our focus is a multiple-targeted universal CAR T system with the potential to improve the lives of millions of patients across the world who are suffering from a wide range of malignancies.